Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions of people worldwide every day. Reuters provides business, financial ...

Miki Sogi, an analyst from Bernstein, maintained the Buy rating on Eisai Co (ESALF – Research Report). The associated price target is ...

Ahead of World Alzheimer’s Month in September, we're learning about this degenerative disease, the importance of early ...

Despite its marketing approval, Leqembi’s cost effectiveness falls short of NICE’s standards to justify wide range use in the ...

Eisai Co Ltd's new patent offers a promising therapeutic agent for treating fatty liver diseases, including NAFLD and NASH, enhancing patient care and management.

The Cambridge drugmaker said this makes Leqembi the first treatment for early Alzheimer's disease that targets an underlying ...

In a decision contrary to its European counterpart, the U.K.'s Medicines and Healthcare products Regulatory Agency (MHRA) has ...

Alzheimer's patients in Britain's state-run health service are unlikely to get access to Eisai and Biogen's new Leqembi drug, ...

Eisai Co., Ltd. (ESALY.PK) and Biogen Inc. (BIIB) announced that the Medicines and Healthcare products Regulatory Agency (MHRA) in ...

Biogen and Eisai's breakthrough Alzheimer's therapy, Leqembi, granted marketing authorization in Great Britain.

Japanese pharma company Eisai (ESAIY) reported positive results in clinical trials of its Alzheimer’s drug Leqembi. This could mean a revolution for administering the drug, which is currently ...

(RTTNews) - Eisai Co., Ltd. (ESALY.PK) and Biogen Inc. (BIIB) announced that the Medicines and Healthcare products Regulatory Agency (MHRA) in Great Britain has granted Marketing Authorization for ...